BNP Paribas Discount Zert SNW 27..../ DE000PC0NTD5 /
2024-04-29 9:40:11 PM | Chg.-0.320 | Bid9:59:53 PM | Ask9:59:53 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
88.450EUR | -0.36% | 88.160 Bid Size: 300 |
89.110 Ask Size: 300 |
SANOFI SA INHABER ... | - - | 2024-06-27 | Call |
GlobeNewswire
1:00 PM
EYLEA® HD (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Sustained and Clinically Mean...
GlobeNewswire
04-25
Press Release: Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance
GlobeNewswire
04-23
Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia
GlobeNewswire
04-17
Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in ...
GlobeNewswire
04-10
Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate Upda...
GlobeNewswire
04-09
Nurix Therapeutics Announces Extension of Strategic Collaboration with Sanofi to Develop Novel Targe...
GlobeNewswire
03-14
MeiraGTx Reports Fourth Quarter and Full Year 2023 Financial and Operational Results and Recent Busi...
GlobeNewswire
03-14
SMDG Announces Appointment of Industry Leader Dr. Zsuzsanna Devecseri to the Board of Directors
GlobeNewswire
03-11
Press Release: New Phase 2b results for amlitelimab support potential for best-in-class maintenance ...
GlobeNewswire
03-05
Tonix Pharmaceuticals Announces Translation of Preclinical Pharmacokinetic Parameters of TNX-1500 (F...
GlobeNewswire
02-28
Tonix Pharmaceuticals Completes Clinical Stage of Phase 1 Trial for TNX-1500 (Fc-modified humanized ...
GlobeNewswire
02-27
Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlig...
GlobeNewswire
02-24
Press Release: Phase 2 results demonstrate rilzabrutinib rapidly reduced itch severity and significa...
GlobeNewswire
02-23
Press Release: Filing of the 2023 U.S. Form 20-F and French “Document d’Enregistrement Universel” co...
GlobeNewswire
02-23
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of COPD with Type 2 Inflam...
GlobeNewswire
02-23
Press Release: Dupixent® sBLA accepted for FDA Priority Review for treatment of COPD with type 2 inf...